Apyx Medical Corporation Common Stock (APYX) — 分析摘要
Apyx Medical Corporation Common Stock(APYX)的市值为179.39百万美元,最近一年的营收同比增长了+9.9%。净利润率为-21.2%。当前市盈率为-19.6倍。
核心要点
- 营收同比变化+9.9%
- 净利润率-21.2%
- 市盈率-19.6倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,APYX的营收增长为+9.9%,市盈率为-19.6倍。
Apyx Medical Corporation Common Stock (APYX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -0.8x — 盈利不足以覆盖利息支出
最新报表显示自由现金流为负。
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
205
总部
CLEARWATER, FL
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。